Amifostine is indicated for:
Population group: both men and women, only adults (18 - 65 years old)
Amifostine is indicated to reduce the cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: both men and women, only adults (18 - 65 years old)
Amifostine is indicated to reduce the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer, where the radiation port includes a substantial portion of the parotid glands.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Amifostine is contraindicated in the following cases: